Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Daniele Laszlò et al.|Journal of Clinical Oncology|2015Cited by 63
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A. Moccia, Emanuele Zucca, Christian Taverna et al.|Blood Advances|2020Cited by 25
Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Giovanni Martinelli et al.|Blood|2013Cited by 13
Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Stéphanie Rondeau et al.|Blood|2018Cited by 1